基于“宿痰伏肺”理论干预支气管哮喘缓解期临床疗效及免疫功能研究  

Study of Clinical Effect and Immune Function Change of Traditional Chinese Medicine Intervening Asthma in Remission Stage Based on the Theory of “Latent Phlegm in the Lung”

作　　者：石绍顺[1] 于雪峰[1] 李国信[1] 李中宇[1] 

机构地区：[1]辽宁中医药大学附属第二医院,辽宁沈阳110034

出　　处：《山东中医杂志》2016年第9期774-776,共3页Shandong Journal of Traditional Chinese Medicine

基　　金：国家中医药管理局临床重点专科项目

摘　　要：目的:评价"宿痰伏肺"理论干预支气管哮喘缓解期的可行性。方法:将241例支气管哮喘缓解期患者随机分为治疗组122例和对照组119例,治疗组连续口服金龙固本合剂,对照组不予干预,观察疾病复发率、血T淋巴细胞亚群(CD4^+、CD8^+)水平等指标。结果:疾病复发率治疗组总有效率96.46%,对照组总有效率62.73%,两组间比较差异有显著统计学意义(P<0.01)。随访360 d,治疗组CD4^+水平较治疗前明显升高(P<0.01);对照组CD8^+水平较治疗组明显升高(P<0.01)。结论:基于"宿痰伏肺"理论研制的金龙固本合剂能明显减少支气管哮喘发作次数,具有调节免疫功能作用,为哮喘缓解期的中医药治疗提供理论依据。Objective：To explore the feasibility of traditional Chinese medicine（TCM） intervening asthma in remission stage based on the theory of ＂Latent phlegm in the lung＂. Methods：Totally 241 cases of asthma in remission stage were randomized into the control group and the treatment group treated. The treatment group with 122 patients was given Jinlong Guben mixture,while the control group with 119 patients was given no treatment. The total effective rate,peripheral blood CD4^＋and CD8^＋,were observed. Results：The total effective rates were 96.46% in the treatment group and 62.73% in the control group,with significant difference between the two groups（P〈0.01）. After 360 days,in the treatment group peripheral blood CD4^＋ level were significantly increased than that before the treatment（P〈0.01）,while in the control group peripheral blood CD8^＋level were significantly increased than that before the treatment（P〈0.01）. Conclusions：Based on the theory of ＂latent phlegm in the lung＂ Jinlong Guben mixture could significantly reduce the recurrence of asthma,regulate the immune function. This study will provide a theoretical basis for TCM intervening asthma in the remission stage.

关 键 词：宿痰伏肺 支气管哮喘缓解期 T淋巴细胞 

分 类 号：R256.12[医药卫生—中医内科学]